Genmab gains as Goldman upgrades stock to Buy on increased pipeline confidence

Goldman Sachs upgraded Genmab to Buy from Neutral, citing growing confidence in three pipeline assets that could de-risk more than $5 billion in peak sales potential. Goldman sees Rina-S at $1.9 billion risk-adjusted peak sales in gynecological oncology, petosemtamab at $2.1 billion in head and neck cancer, and Epkinly at $3.1 billion, with multiple readouts expected in 2026. Shares rose 2.5% in Copenhagen and nearly 4% in U.S. premarket trading, while the firm said Darzalex royalty expiry from 2029 is already reflected in the stock.

Analysis

The upgrade is less about near-term upside in Genmab and more about a market regime shift: the stock is moving from a single-royalty comp to a multi-shot pipeline story. That matters because the marginal buyer can now underwrite a staggered sequence of data events through 2H26, which compresses perceived binary risk and typically supports a higher multiple well before revenue inflects. In other words, the catalyst path is now visible enough to pull forward de-risking into the stock long before any of the readouts hit.

The bigger second-order effect is on the competitive set in antibody-drug conjugates and bispecifics. If Rina-S and petosemtamab continue to look differentiated, late-stage competitors in gyn-onc and head-and-neck will face a tougher financing and partnering environment, because Genmab’s valuation can become a public-market reference point for what “good” looks like in these modalities. That can also pressure smaller peers with similar mechanisms but weaker data packages, since capital tends to re-rate to the best-in-class read-through rather than the broad space.

The contrarian issue is that the market may be too focused on peak-sales math and not enough on pathway risk and timing slippage. Even if accelerated approval is delayed, the DCF hit is limited, but the stock can still derate on timeline drift if the 2H26 cadence slips into 2027; biotech multiples are highly sensitive to visible event density. Separately, the 2029 royalty fade is a longer-duration headwind that likely caps upside in the absence of a sustained multiple expansion, so this is still a story of asset optionality rather than clean earnings compounding.

Key Decisions for Investors

• Go long GMAB on a 3-6 month horizon into the next readout window; use pullbacks to build. Risk/reward is favorable if the market continues to price multiple shots on goal, but trim ahead of each binary catalyst if implied volatility compresses.
• Pair trade: long GMAB vs short a basket of single-asset oncology names with similar timelines but weaker validation. The thesis is that Genmab is the higher-quality de-risking vehicle and should attract relative inflows as data visibility improves.
• For event-driven accounts, buy GMAB call spreads 6-9 months out to express upside to pipeline de-risking while capping premium burn. Best setup is post-rally consolidation, when implied volatility has not fully caught up to the catalyst calendar.
• Avoid chasing the move after a single positive read-through; the better entry is on any setback tied to broader biotech risk-off or if the market re-prices the royalty fade. The stock’s longer-term ceiling is likely constrained until the market sees durable post-2026 replacement economics.
• Monitor competitor names in ADC and bispecific spaces for sympathetic weakness; if Genmab’s assets continue to validate, use that as a relative-value signal to underweight peers with less differentiated data.